Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured In Recent Research Report By Zacks SCR

(MENAFN- Investor Brand Network)

• Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms
• The report discusses the company's ongoing research and development (“R&D”) programs, forecasting penetration into global markets for hypertension, oral nicotine delivery, and antiviral product categories
• Lexaria is targeting conditions with significant market potential, including hypertension, diabetes, dementia, and seizures
• These programs position the company for entry into collaborative opportunities to support further growth and provide growth capital

Lexaria Bioscience (NASDAQ: LEXX) , a global innovator in drug delivery platforms, featured in a recently released research report from Zacks Small-Cap Research (“SCR”) ( ). The report considers the potential approval and commercialization of products processed with the company's patented DehydraTECH(TM) drug delivery platform technology that increases drug bioavailability, and ongoing research and development (“R&D”) activities, including recent revelations that the platform technology may offer a new mechanism of action, to support a $14.00 share valuation ( ).

“DehydraTECH offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels and AUC (area under the curve), brain permeation, taste masking, and side effect reduction. As DehydraTECH does not employ a covalent bond, [it] is not a new molecular...

Read More>>

NOTE TO INVESTORS:
The latest news and updates relating to LEXX are available in the company's newsroom at

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing
CBDNewsBreaks
crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have questions or are you interested in working with CNW?
Ask Our Editor

CBDWire (CBDW)
Denver, Colorado

303.498.7722 Office
[email protected]

CBDWire is part of the
InvestorBrandNetwork .

MENAFN20122024000224011066ID1109015580